$Repare Therapeutics(RPTX.US)$ NEWS Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs. The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
$Repare Therapeutics(RPTX.US)$Especially the MINOTAUR phase 1 Data release soon? 2024 Outlook: •Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
Repare Therapeutics' low P/S ratio is likely due to poor revenue performance and negative growth forecasts. The company's poor outlook compared to other industry players justifies its low P/S ratio.
The company's falling revenue and high cash burn relative to its market value are concerning. Despite a promising cash runway, the cash burn situation is considered a bit risky and causes some nervousness about the stock.
Repare Therapeutics' shrinking revenues and declining revenue forecast could challenge its P/S maintenance, possibly hindering significant share price growth. Its low P/S is acceptable to shareholders considering future revenue stagnation.
$Repare Therapeutics(RPTX.US)$Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
Repare Therapeutics股票讨论区
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
Some dates to watch for!
•Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
加油,继续看好,大盘这么惨,依然很硬
可能会被收购
第一目标14.5美元
暂无评论